Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his 'Liberation Day' ...

FTSE 100 p harma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about ... up to its next earnings release, or is Glaxo due for a pullback? Before we dive into how ...

GSK reported core earnings of 59 cents per American ... digit percentage from prior expectation of being stable. Currently, Glaxo has an average Growth Score of C, a grade with the same score ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where GSK plc (NYSE: GSK) stands against the other most undervalued ...